Replies to post #80817 on Biotech Values

[drbio45]

>US approval in 4Q 2009 ??

I hope so ..

http://reports.finance.yahoo.com/w0?r=45713429:2

Developments Intelgenx announced that the FDA has finished its preliminary review and accepted Intelgenx’s NDA filing for CPI-300, a 450mg extended release Bupropion tablet. Impact Positive. Intelgenx is keeping to its timeline and we should see the tablet approved by Q4/09 and on the market by Q1/10. Comments The FDA has begun its full review of Intelgenx’s 450mg Bupropion tablet, which is excellent news for the company and maintains their timeline. <

Intelgenx is a good story but why do you have to post possible approval in 4q 2009? The pdufa is february 2010, that story is good enough, by posting the other stuff it diminishes the true story.